IntelGenx Technologies Corp. (IGXT)
USD 0.17
(0.0%)
USD 0.17
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 8.79 Million USD | -3.82% |
| 2022 | 8.5 Million USD | 17.13% |
| 2021 | 7.26 Million USD | -7.01% |
| 2020 | 7.8 Million USD | -24.14% |
| 2019 | 10.29 Million USD | -4.9% |
| 2018 | 10.82 Million USD | 47.94% |
| 2017 | 7.31 Million USD | 24.36% |
| 2016 | 5.88 Million USD | 79.55% |
| 2015 | 3.27 Million USD | -4.74% |
| 2014 | 3.43 Million USD | 32.93% |
| 2013 | 2.58 Million USD | -24.22% |
| 2012 | 3.41 Million USD | 18.3% |
| 2011 | 2.88 Million USD | -33.49% |
| 2010 | 4.33 Million USD | 69.16% |
| 2009 | 2.56 Million USD | -19.04% |
| 2008 | 3.16 Million USD | 102.45% |
| 2007 | 1.56 Million USD | 51.51% |
| 2006 | 1.03 Million USD | 10327.23% |
| 2005 | 9906.00 USD | 31.29% |
| 2004 | 7545.00 USD | 6886.11% |
| 2003 | 108.00 USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 2.92 Million USD | 74.42% |
| 2023 Q2 | 2.22 Million USD | -3.55% |
| 2023 Q3 | 2.2 Million USD | -0.99% |
| 2023 FY | 8.18 Million USD | -3.82% |
| 2023 Q4 | 1.67 Million USD | -23.95% |
| 2023 Q1 | 2.3 Million USD | 3.82% |
| 2022 Q1 | 2.07 Million USD | -11.35% |
| 2022 FY | 8.5 Million USD | 17.13% |
| 2022 Q2 | 2.1 Million USD | 1.11% |
| 2022 Q3 | 2.1 Million USD | 0.19% |
| 2022 Q4 | 2.22 Million USD | 5.7% |
| 2021 Q1 | 1.59 Million USD | -9.7% |
| 2021 FY | 7.26 Million USD | -7.01% |
| 2021 Q2 | 1.59 Million USD | -0.06% |
| 2021 Q4 | 2.34 Million USD | 35.04% |
| 2021 Q3 | 1.73 Million USD | 9.05% |
| 2020 Q4 | 1.76 Million USD | -7.16% |
| 2020 Q3 | 1.89 Million USD | 5.91% |
| 2020 Q1 | 2.35 Million USD | -3.57% |
| 2020 FY | 7.8 Million USD | -24.14% |
| 2020 Q2 | 1.79 Million USD | -23.8% |
| 2019 Q1 | 2.73 Million USD | -4.4% |
| 2019 Q4 | 2.44 Million USD | -5.5% |
| 2019 Q3 | 2.58 Million USD | 1.85% |
| 2019 Q2 | 2.53 Million USD | -7.31% |
| 2019 FY | 10.29 Million USD | -4.9% |
| 2018 Q3 | 3.34 Million USD | 41.77% |
| 2018 Q2 | 2.35 Million USD | 4.34% |
| 2018 Q1 | 2.26 Million USD | 1.76% |
| 2018 FY | 10.82 Million USD | 47.94% |
| 2018 Q4 | 2.86 Million USD | -14.42% |
| 2017 Q4 | 2.22 Million USD | 28.68% |
| 2017 FY | 7.31 Million USD | 24.36% |
| 2017 Q3 | 1.72 Million USD | 4.61% |
| 2017 Q2 | 1.65 Million USD | -3.96% |
| 2017 Q1 | 1.71 Million USD | 23.69% |
| 2016 Q2 | 1.4 Million USD | -4.04% |
| 2016 Q4 | 1.38 Million USD | -14.99% |
| 2016 FY | 5.88 Million USD | 79.55% |
| 2016 Q3 | 1.63 Million USD | 16.71% |
| 2016 Q1 | 1.45 Million USD | 35.09% |
| 2015 FY | 3.27 Million USD | -4.74% |
| 2015 Q4 | 1.08 Million USD | 28.11% |
| 2015 Q2 | 827 Thousand USD | 57.22% |
| 2015 Q1 | 526 Thousand USD | -51.83% |
| 2015 Q3 | 843 Thousand USD | 1.93% |
| 2014 Q2 | 786 Thousand USD | 18.37% |
| 2014 FY | 3.43 Million USD | 32.93% |
| 2014 Q4 | 1.09 Million USD | 21.74% |
| 2014 Q3 | 897 Thousand USD | 14.12% |
| 2014 Q1 | 664 Thousand USD | -15.63% |
| 2013 Q4 | 787 Thousand USD | 12.59% |
| 2013 FY | 2.58 Million USD | -24.22% |
| 2013 Q3 | 699 Thousand USD | 52.62% |
| 2013 Q2 | 458 Thousand USD | -28.77% |
| 2013 Q1 | 643 Thousand USD | -55.0% |
| 2012 Q3 | 651 Thousand USD | -6.33% |
| 2012 Q4 | 1.42 Million USD | 119.51% |
| 2012 FY | 3.41 Million USD | 18.3% |
| 2012 Q1 | 818 Thousand USD | -7.88% |
| 2012 Q2 | 695 Thousand USD | -15.04% |
| 2011 Q1 | 698 Thousand USD | -38.99% |
| 2011 Q2 | 575 Thousand USD | -17.62% |
| 2011 Q4 | 888 Thousand USD | 22.48% |
| 2011 Q3 | 725 Thousand USD | 26.09% |
| 2011 FY | 2.88 Million USD | -33.49% |
| 2010 Q2 | 1.06 Million USD | 11.95% |
| 2010 Q1 | 954 Thousand USD | 26.53% |
| 2010 FY | 4.33 Million USD | 69.16% |
| 2010 Q3 | 1.17 Million USD | 9.83% |
| 2010 Q4 | 1.14 Million USD | -2.47% |
| 2009 Q2 | 454 Thousand USD | -31.49% |
| 2009 Q3 | 694.4 Thousand USD | 52.95% |
| 2009 Q1 | 662.7 Thousand USD | 95.93% |
| 2009 FY | 2.56 Million USD | -19.04% |
| 2009 Q4 | 754 Thousand USD | 8.58% |
| 2008 Q4 | 338.23 Thousand USD | -69.59% |
| 2008 Q1 | 580.5 Thousand USD | 61.37% |
| 2008 Q2 | 1.13 Million USD | 95.96% |
| 2008 Q3 | 1.11 Million USD | -2.23% |
| 2008 FY | 3.16 Million USD | 102.45% |
| 2007 Q2 | 359.42 Thousand USD | 68.95% |
| 2007 Q3 | 583.24 Thousand USD | 62.27% |
| 2007 Q4 | 359.72 Thousand USD | -38.32% |
| 2007 FY | 1.56 Million USD | 51.51% |
| 2007 Q1 | 212.74 Thousand USD | -55.98% |
| 2006 Q3 | 262.09 Thousand USD | 44.37% |
| 2006 Q4 | 483.28 Thousand USD | 84.4% |
| 2006 FY | 1.03 Million USD | 10327.23% |
| 2006 Q1 | 1238.00 USD | -52.11% |
| 2006 Q2 | 181.54 Thousand USD | 14563.97% |
| 2005 Q1 | 3542.00 USD | 104.03% |
| 2005 Q3 | 1884.00 USD | -0.58% |
| 2005 FY | 9906.00 USD | 31.29% |
| 2005 Q4 | 2585.00 USD | 37.21% |
| 2005 Q2 | 1895.00 USD | -46.5% |
| 2004 Q3 | 2746.00 USD | -10.35% |
| 2004 Q4 | 1736.00 USD | -36.78% |
| 2004 FY | 7545.00 USD | 6886.11% |
| 2004 Q2 | 3063.00 USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2003 FY | 108.00 USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| HST Global, Inc. | 140.9 Thousand USD | -6143.125% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -852.561% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -5029.177% |
| CytoDyn Inc. | 18.05 Million USD | 51.285% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 89.764% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| MultiCell Technologies, Inc. | 567.42 USD | -1550250.71% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -384.331% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -74.473% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 35288.0% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -4747.233% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Alpha Cognition Inc. | 9.7 Million USD | 9.362% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 84.685% |
| SQZ Biotechnologies Company | 85.61 Million USD | 89.725% |
| Resverlogix Corp. | 12.71 Million USD | 30.798% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -2158.154% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -0.202% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -258.284% |
| Mesoblast Limited | 5.9 Million USD | -49.051% |
| GB Sciences, Inc. | 1.42 Million USD | -519.285% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -852.561% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 70.233% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -158.357% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -30.946% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -140.967% |
| ContraFect Corporation | 56.88 Million USD | 84.537% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -215.264% |
| BioStem Technologies, Inc. | 22.97 Million USD | 61.71% |
| LadRx Corporation | 3.81 Million USD | -130.784% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 45.054% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -686.148% |
| CSL Limited | 3.44 Billion USD | 99.745% |
| Biomind Labs Inc. | 994.18 Thousand USD | -784.848% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -555.736% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 76.387% |
| Nascent Biotech, Inc. | 2.22 Million USD | -294.506% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 89.863% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -78.877% |
| GeneThera, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 64.406% |
| Adynxx, Inc. | - USD | -Infinity% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -485.725% |
| Marizyme, Inc. | 19.23 Million USD | 54.277% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -5.492% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -519.598% |
| Zenith Capital Corp. | 8.94 Million USD | 1.633% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -201.656% |
| Halberd Corporation | 74.84 Thousand USD | -11654.095% |
| Genus plc | 147.7 Million USD | 94.044% |
| Pharming Group N.V. | 225.49 Million USD | 96.099% |
| MetaStat, Inc. | - USD | -Infinity% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -329.393% |
| IMV Inc. | 37.7 Million USD | 76.671% |
| Affymax, Inc. | 39.38 Million USD | 77.665% |
| SYBLEU INC | 160.87 Thousand USD | -5368.187% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -742.625% |
| Enzolytics Inc. | 2.17 Million USD | -303.623% |
| argenx SE | 1.53 Billion USD | 99.426% |
| AVAX Technologies, Inc. | 7.31 Million USD | -20.338% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -494.894% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -558.739% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | 3.74 Million USD | -134.811% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -34851.726% |
| Cell Source, Inc. | 4.32 Million USD | -103.383% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -1553.69% |
| Q BioMed Inc. | 3.43 Million USD | -155.978% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -107.554% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 19.048% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -234.802% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -99.539% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 91.144% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -399.921% |
| Rebus Holdings, Inc. | 664 Thousand USD | -1224.849% |
| Helix BioMedix, Inc. | 1.97 Million USD | -346.088% |
| Skye Bioscience, Inc. | 13.54 Million USD | 35.066% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -371.848% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -357.961% |
| ONE Bio Corp. | 6.44 Million USD | -36.517% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -379.376% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -682.018% |
| Agentix Corp. | 1.37 Million USD | -541.295% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -265.79% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -457.0% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -50396.527% |
| Kadimastem Ltd | 2.41 Million USD | -265.004% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -3261.149% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -2017.315% |
| NovAccess Global Inc. | 2.46 Million USD | -256.621% |
| Itoco Inc. | 919.14 Thousand USD | -857.087% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -3897.219% |
| Qrons Inc. | 643.67 Thousand USD | -1266.679% |
| Mobile Lads Corp. | 554.54 Thousand USD | -1486.343% |
| Genscript Biotech Corporation | 825.34 Million USD | 98.934% |
| International Stem Cell Corporation | 5.27 Million USD | -66.894% |
| Bioxytran, Inc. | 3.82 Million USD | -130.279% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -16610.991% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -43143.376% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 75.743% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -443.696% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -1095.513% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -182.771% |
| Neutra Corp. | 243.82 Thousand USD | -3507.975% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 49.608% |
| PureTech Health plc | 144.59 Million USD | 93.916% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 57.067% |
| IXICO plc | 4.7 Million USD | -86.892% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 92.529% |
| CSL Limited | 3.89 Billion USD | 99.774% |
| Cellectis S.A. | 97.32 Million USD | 90.961% |